Tsugiyasu Kanda, Masayuki Mori, Nobuo Kato and Yasuhiro Kawasaki
Kanazawa Medical University, Japan
Posters & Accepted Abstracts: J Diabetes Metab
Objective: Obesity has been associated with cognitive deficits and even dementia, accordingly the metabolic abnormalities such as diabetes. We hypothesized anti-diabetic agent, alogliptin and DPP4 inhibitor affect on cognition deficits and metabolic abnormality. Methods: Three months oral administration of alogliptin (30 mg/kg/day) were performed in ApoE-/- mice with high-fat diet (HFA, n=15). The non-treated mice with high-fat diet (HFD, n=15) became obese. Mice were fed from the age of 8 weeks until 20 weeks. As a control, non-exercised mice without high-fat diet (NOR, n=15) were prepared. Morris water maze test as spatial learning and novel object recognition test as recognition memory were performed. Forced swimming test as depressive state was also performed. Results: Mice in HFD showed cognition deficits, depressive condition and metabolic abnormality. The alogliptin treatment did not reduce the body weight compared with non-exercised mice with high-fat diet (HFA; 46.5±5.9 g vs. HFD; 49.7±2.7 g vs. NOR; 30.4±1.6 g, P<0.05). The liver weight/ body weight ratio was significantly reduced in HFA compared with HFD (HFA; 59±17 x10-3 vs. HFD; 76±18 x10-3 vs. NOR; 48±9 x10-3, P<0.05). The circulating levels of liver enzyme and triglyceride were significantly lower in HFA compared with HFD. Both Morris water maze test and novel object recognition test were significantly recovered in HFA compared with HFD. The forced swimming test was also recovered in HFA compared with HFD. Conclusions: We could mention that alogliptin treatment could attenuate cognitive deficit and depressive function in association with metabolic advantages.
Email: kandat@kanazawa-med.ac.jp
